Index
S&P 500
Market Cap
29.31B
Enterprise Value
35.84B
Income
1.00B
Sales
14.59B
Book/sh
108.96
Cash/sh
3.23
Employees
71000
IPO
Jul 07, 1988
P/E
29.64
Forward P/E
18.34
PEG
1.91
P/S
2.01
P/B
3.32
P/C
111.95
P/FCF
22.77
EV/EBITDA
15.24
EV/Sales
2.46
Quick Ratio
1.22
Current Ratio
1.41
Debt/Eq
0.77
LT Debt/Eq
0.68
Option/Short
Yes / Yes
EPS (ttm)
12.19
EPS next Y
19.70
EPS next Q
4.51
EPS this Y
12.32%
EPS next Y
6.70%
EPS next 5Y
9.61%
EPS past 3/5Y
-9.18% -8.01%
Sales past 3/5Y
5.55% -0.04%
EPS Y/Y TTM
19.63%
Sales Y/Y TTM
6.02%
EPS Q/Q
3.24%
Sales Q/Q
6.92%
Insider Own
0.40%
Insider Trans
-4.98%
Inst Own
101.21%
Inst Trans
-1.24%
ROA
5.40%
ROE
11.45%
ROIC
6.77%
Gross Margin
26.87%
Oper. Margin
11.26%
Profit Margin
6.88%
SMA20
10.79%
SMA50
11.81%
SMA200
25.68%
Trades
Shs Outstand
81.20M
Shs Float
80.77M
52W High
371.00 -2.59%
52W Low
244.52 47.80%
Volatility
4.03% 2.66%
ATR (14)
10.21
RSI (14)
74.54
Beta
0.89
Rel Volume
1.06
Avg Volume
726.81K
Volume
773,783
Perf Week
9.86%
Perf Month
18.64%
Perf Quarter
17.56%
Perf Half Y
41.26%
Perf YTD
44.05%
Perf Year
43.22%
Perf 3Y
82.37%
Perf 5Y
46.57%
Perf 10Y
239.25%
Prev Close
368.16
Price
361.39
Change %
-1.84%
Analysts 13 incl. previous ratings
Rating Distribution 8 Buy · 4 Hold · 1 Sell
Date Action Analyst Rating Change Price Target Change Implied Upside Jul 10, 2025 Downgrade H HSBC Securities
Buy → Hold $260 -28.1% Apr 02, 2025 Initiated R Redburn Atlantic
Buy $276 -23.6% Mar 04, 2025 Upgrade C Citigroup
Neutral → Buy $250 → $300 -17.0% Jan 07, 2025 Upgrade E Evercore ISI
In-line → Outperform $260 → $265 -26.7% Dec 10, 2024 Resumed J Jefferies
Buy $265 → $275 -23.9% Oct 30, 2024 Upgrade H HSBC Securities
Hold → Buy Oct 01, 2024 Initiated P Piper Sandler
Neutral $235 -35.0% Mar 25, 2024 Upgrade A Argus
Hold → Buy $250 -30.8% Feb 26, 2024 Initiated L Leerink Partners
Outperform $260 -28.1% Feb 09, 2024 Initiated E Evercore ISI
In-line $240 -33.6% Jan 03, 2024 Initiated B Barclays
Equal Weight $222 -38.6% Sep 06, 2023 Initiated H HSBC Securities
Hold $210 -41.9% Dec 12, 2022 Downgrade C Citigroup
Buy → Neutral $275 → $250 -30.8% Sep 19, 2022 Downgrade A Argus
Buy → Hold Aug 22, 2022 Resumed M Morgan Stanley
Overweight $300 -17.0% Jan 28, 2022 Downgrade D Deutsche Bank
Buy → Hold $330 → $294 -18.6% Jan 11, 2021 Upgrade A Argus
Hold → Buy $245 -32.2% Jan 11, 2021 Downgrade W Wolfe Research
Peer Perform → Underperform Jan 08, 2021 Downgrade W Wolfe Research
Outperform → Peer Perform Jul 14, 2020 Upgrade B BofA Securities
Neutral → Buy $194 → $220 -39.1%
Show Previous Ratings
Oct-30-26 01:13PM
Oct-28-26 04:30PM
02:37PM
01:56PM
12:03PM
11:22AM
Loading…
11:22AM
07:22AM
06:50AM
Oct-23-26 08:00AM
Oct-22-26 04:30PM
Oct-21-26 06:50AM
Oct-20-26 11:45AM
Oct-15-26 09:45AM
07:30AM
Oct-13-26 08:00AM
06:53PM
Loading…
Oct-12-26 06:53PM
Oct-08-26 05:39PM
Sep-30-26 08:30AM
Sep-22-26 07:55AM
Sep-10-26 04:30PM
07:00AM
Sep-09-26 08:55AM
Sep-08-26 09:05AM
Aug-31-26 03:29PM
07:00AM
Aug-28-26 08:30AM
Aug-24-26 07:02AM
Aug-20-26 03:21PM
Aug-18-26 07:00AM
Aug-17-26 08:00AM
07:00AM
Loading…
Aug-10-26 07:00AM
Aug-04-26 07:00AM
Jul-30-26 05:38PM
05:08PM
06:58AM
06:50AM
Jul-27-26 08:00AM
Jul-09-26 05:05PM
Jun-30-26 04:15PM
Jun-22-26 07:00AM
May-29-26 07:19AM
07:00AM
May-28-26 07:00AM
May-27-26 08:00AM
May-20-26 07:00AM
May-14-26 06:00AM
May-12-26 07:00AM
Apr-30-26 07:00AM
06:50AM
Apr-24-26 08:00AM
Apr-22-26 07:00AM
Apr-15-26 07:00AM
Apr-14-26 07:00AM
Apr-13-26 08:30AM
Apr-09-26 06:50AM
Mar-31-26 04:15PM
Mar-23-26 06:00AM
Mar-18-26 09:15AM
Mar-09-26 08:25AM
Mar-06-26 09:40AM
07:00AM
Mar-04-26 08:14AM
Feb-27-26 12:44PM
01:12AM
Feb-24-26 11:31PM
12:33AM
Feb-23-26 07:00AM
Feb-19-26 09:50AM
07:21AM
Feb-18-26 02:34PM
09:40AM
12:32AM
Feb-17-26 04:00PM
02:00PM
01:46PM
11:11AM
10:35AM
10:07AM
09:30AM
08:00AM
07:09AM
(Associated Press Finance)
07:01AM
06:50AM
Feb-15-26 10:07PM
Feb-13-26 08:29PM
Feb-11-26 12:10PM
10:00AM
09:15AM
07:00AM
Feb-10-26 09:20PM
08:57AM
Feb-09-26 01:54PM
08:30AM
Feb-05-26 07:38PM
Feb-03-26 08:10AM
Jan-26-26 09:40AM
Jan-21-26 08:30AM
Jan-15-26 04:34PM
04:15PM
Jan-14-26 06:50AM
Show Previous News
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Parham Richelle P Director Oct 30 '26 Proposed Sale 361.22 1,078 389,395 Oct 30 11:48 AM ANDERSON KERRII B Director Aug 17 '26 Sale 318.02 3,000 954,060 6,563 Aug 18 08:10 AM KERRII B ANDERSON Director Aug 17 '26 Proposed Sale 318.13 3,000 954,390 Aug 17 04:31 PM Schechter Adam H President & CEO Aug 11 '26 Sale 320.37 4,669 1,495,808 102,565 Aug 12 02:31 PM Schechter Adam H Officer Aug 11 '26 Proposed Sale 320.37 4,669 1,495,808 Aug 11 10:06 AM Summy Amy B. EVP, Chief Marketing Officer Aug 04 '26 Sale 306.74 924 283,428 6,956 Aug 06 08:26 AM Wilkinson Peter J SVP, Chief Accounting Officer Aug 03 '26 Option Exercise 209.25 1,338 279,976 3,108 Aug 05 11:17 AM Wilkinson Peter J SVP, Chief Accounting Officer Aug 03 '26 Sale 309.23 1,420 439,107 1,770 Aug 05 11:17 AM Summy Amy B. Officer Aug 04 '26 Proposed Sale 306.74 924 283,428 Aug 04 11:58 AM Kyle Kathryn W EVP, Chief Legal Officer Jul 02 '26 Sale 286.19 92 26,329 3,904 Jul 06 09:37 AM Vaughn Bryan T EVP and President, Diagnostics Jul 02 '26 Sale 286.19 234 66,968 6,746 Jul 06 09:36 AM Kyle Kathryn W Officer Jul 02 '26 Proposed Sale 286.19 92 26,329 Jul 02 12:19 PM Vaughn Bryan T Officer Jul 02 '26 Proposed Sale 286.19 234 66,968 Jul 02 10:29 AM van der Vaart Sandra D Former Officer Jul 01 '26 Proposed Sale 280.48 7,138 2,002,066 Jul 01 10:03 AM Kyle Kathryn W EVP, Chief Legal Officer Jun 08 '26 Sale 263.89 762 201,084 3,813 Jun 10 09:01 AM Kyle Kathryn W Officer Jun 08 '26 Proposed Sale 263.89 762 201,084 Jun 08 12:19 PM Schechter Adam H President & CEO May 11 '26 Sale 254.50 5,903 1,502,314 107,234 May 13 09:30 AM Schechter Adam H Officer May 11 '26 Proposed Sale 254.50 5,903 1,502,314 May 11 09:51 AM van der Vaart Sandra D Former Officer May 06 '26 Proposed Sale 256.76 6,238 1,601,649 May 06 10:40 AM Wilkinson Peter J SVP, Chief Accounting Officer Mar 27 '26 Sale 267.05 1,633 436,093 1,852 Mar 30 12:54 PM Meltzer Jonathan C EVP, Operations Mar 27 '26 Sale 267.05 839 224,055 3,620 Mar 30 12:44 PM Meltzer Jonathan C Officer Mar 27 '26 Proposed Sale 267.05 839 224,055 Mar 27 10:40 AM Schechter Adam H President & CEO Mar 03 '26 Sale 279.96 8,705 2,437,047 80,773 Mar 05 08:57 AM Schechter Adam H Officer Mar 03 '26 Proposed Sale 279.96 8,705 2,437,047 Mar 03 12:23 PM van der Vaart Sandra D EVP, Corporate Affairs Feb 27 '26 Sale 284.91 548 156,000 2,579 Mar 03 10:41 AM van der Vaart Sandra D Officer Feb 27 '26 Proposed Sale 284.67 548 156,000 Feb 27 09:40 AM Caveney Brian J EVP, Pres of ED, CMO & CSO Feb 24 '26 Sale 286.31 1,500 429,458 30,107 Feb 26 08:25 AM Caveney Brian J Officer Feb 24 '26 Proposed Sale 286.31 1,500 429,458 Feb 24 01:50 PM Wilkinson Peter J SVP, Chief Accounting Officer Feb 19 '26 Sale 277.94 666 185,108 1,852 Feb 23 09:13 AM Schechter Adam H President & CEO Feb 11 '26 Sale 284.38 5,273 1,499,536 87,343 Feb 13 01:13 PM Meltzer Jonathan C EVP, Operations Feb 12 '26 Sale 290.42 87 25,267 2,782 Feb 13 01:11 PM Meltzer Jonathan C EVP, Operations Feb 10 '26 Sale 276.79 91 25,188 2,696 Feb 12 03:44 PM Meltzer Jonathan C Officer Feb 12 '26 Proposed Sale 290.42 87 25,267 Feb 12 09:49 AM Schechter Adam H Officer Feb 11 '26 Proposed Sale 284.38 5,273 1,499,536 Feb 11 12:59 PM Meltzer Jonathan C EVP, Operations Feb 09 '26 Sale 275.53 88 24,247 2,869 Feb 10 03:04 PM Meltzer Jonathan C Officer Feb 10 '26 Proposed Sale 276.79 91 25,188 Feb 10 10:30 AM Meltzer Jonathan C Officer Feb 09 '26 Proposed Sale 275.53 88 24,247 Feb 09 01:30 PM Schechter Adam H President & CEO Nov 11 '25 Sale 262.75 5,745 1,509,499 87,574 Nov 13 08:47 AM Schechter Adam H Officer Nov 11 '25 Proposed Sale 262.75 5,745 1,509,499 Nov 12 06:54 AM
Labcorp Holdings, Inc. provides laboratory services to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates through the Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS) segments. The Dx segment includes routine and specialty esoteric testing. The BLS segment consists of central laboratory and ED businesses. The company was founded in 1995 and is headquartered in Burlington, NC.
President Mr. Adam H. Schechter
M.D. Dr. Brian J. Caveney J.D.
Senior VP & Chief Accounting Officer Mr. Peter J. Wilkinson
Ph.D. Mr. Akinbolade Oyegunwa M.B.A.
Senior Vice President of Investor Relations Mr. Dewey Steadman C.F.A.